Prostate Cancer Spread may be Delayed With Apalutamide
Apalutamide - drug under development for prostate cancer yields promising result The progress of prostate cancer may be slowed down by treatment with the drug apalutamide. Research at the Massachusetts General Hospital finds that treatment with the investigational androgen receptor inhibitor - apalutamide, significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer